ABBVIE said Health Canada has issued a Notice of Compliance with Conditions for Venclexta (venetoclax). The therapy has been approved for previously treated chronic lymphocytic leukemia patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional... […]
FOUNDATION MEDICINE, INC. announced the addition of new clinical markers to its FoundationOne and FoundationOne Heme products, which are designed to enhance oncologists’ insight into potential response to immunotherapies. This ability to determine TMB and MSI from its assays is additional to the existing comprehensive profiling of genes provided by FoundationOne and FoundationOne Heme. Taken... […]
GENENTECH, a member of the Roche Group, received a second Breakthrough Therapy Designation from FDA for its anaplastic lymphoma kinase inhibitor, Alecensa (alectinib). The latest BTD was granted for the treatment of adult patients with advanced ALK-positive non-small cell lung cancer who have not received prior treatment with an ALK inhibitor.
THE US ONCOLOGY NETWORK selected Myriad Genetics as its preferred provider laboratory for hereditary cancer testing. As part of the collaboration, Myriad and The US Oncology Network will work together to perform hereditary cancer research through the Genetic Risk Evaluation and Testing program within The Network affiliated practices. Under this program, the two organizations will... […]
GAMIDA CELL said FDA has granted Breakthrough Therapy Designation to the company’s lead product candidate, NiCord, in development as a novel graft modality for bone marrow transplantation in patients with high risk hematological malignancies. The international, multi-center phase III registration study of NiCord is planned to begin before the end of the year, the company... […]
THE NATIONAL INSTITUTE OF HEALTH AND CARE, England, recommended Eribulin for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimen for advanced disease. In the European Union, The DRUG is indicated as at least one chemotherapeutic regimen and marketing authorization was granted in 2014.... […]
NOVOGEN Ltd. and Genentech entered an agreement to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase pathway. Genentech is a member of the Roche Group. Novogen is an Australian-based company. The lead indication for GDC-0084 is glioblastoma multiforme. GDC-0084 is distinguished from most molecules in the class by its ability to cross... […]
PRONAI THERAPEUTICS INC. announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1). PNT737 is being investigated in two recently initiated Phase I clinical trials, currently sponsored and... […]
NCI ANNOUNCED A COLLABORATION with the Multiple Myeloma Research Foundation to incorporate MMRF's genomic and clinical data about the disease into the NCI Genomic Data Commons, a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology.
THE PRIX GALIEN FOUNDATION announced the nominees for its “Discovery of the Decade” awards covering distinguished industry achievement in medical innovation. This recognition is being held under the sponsorship of the Foundation’s Awards Committee, comprising of nine leaders from academia and industry, including four Nobel Laureates. After ten years of annual awards, the Prix Galien... […]
